Company Overview
Snapshot
Founded in January 1941 by David Fuhrer, Neopharm Group operates with 51–200 employees. In November 2025, the company expanded its Israeli distribution capabilities through its subsidiary Eldan, following an investment in FIZE Medical.
Business overview
Neopharm Group is a family of companies focused on the research, development, manufacturing, marketing, sales, and distribution of healthcare products across more than 60 countries. The company operates in three primary segments: pharmaceutical, consumer healthcare, and medical devices, serving the broader Health Tech & Life Sciences sector.
Strategic signal
In November 2025, Neopharm Group's subsidiary Eldan facilitated an investment in FIZE Medical, a leader in smart fluid management solutions, and expanded its Israeli distribution. This move signals Neopharm's strategic intent to enhance its medical device portfolio and strengthen its market presence in critical care solutions, indicating a focus on innovation and market expansion within the healthcare sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Neopharm Group's primary focus?
- Neopharm Group specializes in the research, development, manufacturing, marketing, sales, and distribution of a diverse range of products within the healthcare market, including pharmaceuticals, consumer healthcare items, and medical devices.
- When was Neopharm Group founded?
- Neopharm Group was founded in January 1941.
- Who is the founder of Neopharm Group?
- David Fuhrer is the founder, owner, Chairman, and CEO of Neopharm Group.
- What was a significant recent business development for Neopharm Group?
- In November 2025, FIZE Medical secured an investment and expanded its Israeli distribution through Eldan, a Neopharm Group company, focusing on smart fluid management solutions for critically ill patients.
- Has Neopharm Group engaged in any strategic partnerships recently?
- In March 2023, Neopharm Group signed a license agreement with Amylyx for an ALS therapy, indicating a strategic focus on expanding its pharmaceutical offerings.